



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B, PTO

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

O I P E  
APR 09 2001  
Sheets

2

of

2

<b>Application Number</b>	09/479,145
<b>Filing Date</b>	January 7, 2000
<b>First Named Inventor</b>	David E. Weinstein
<b>Group Art Unit</b>	1647
<b>Examiner Name</b>	Robert C. Hayes, Ph.D.
<b>Attorney Docket Number</b>	96700/595

<b>OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS</b>		
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
RCH	1.	Gondre et al., Accelerated nerve regeneration mediated by Schwann cells expressing a mutant form of the POU protein SCIP. J. Cell Biol., 141(2):493-501, April 1998.
	2.	Weinstein, D.E., The role of Schwann cells in neural regeneration. The Neuroscientist, 5:208-16, 1999.
	3.	Weinstein, D.E., Isolation and purification of primary rodent astrocytes. In Current Protocols in Neuroscience (NY: John Wiley & Sons, Inc., 1997) 3.5.1-3.5.9.
	4.	Weinstein et al., Premature Schwann cell differentiation and hypermyelination in mice expressing a targeted antagonist of the POU transcription factor SCIP. Mol. Cell Neurosci., 6(3):212-29, June 1995.
	5.	Weinstein et al., Suppression by antisense mRNA demonstrates a requirement for the glial fibrillary acidic protein in the formation of stable astrocytic processes in response to neurons. J. Cell Biol., 112(6):1205-13, March 1991.
	6.	Weinstein et al., C17, a retrovirally immortalized neuronal cell line, inhibits the proliferation of astrocytes and astrocytoma cells by a contact-mediated mechanism. Glia, 3(2):130-39, 1990.
↓	7.	Wu and Weinstein, Isolation and purification of primary Schwann cells. In Current Protocols in Neuroscience (NY: John Wiley & Sons, Inc., 1999) 3.17.1-3.17.9.

TECH CENTER 1600/2900  
APR 12 2001

RECEIVED

1. The citations presented in this statement by the applicant are not intended to be complete or final.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or suggestions regarding this burden statement should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20591.

Please type a plus sign (+) inside this box.

PTO/SB/08A (08-00)

Approved for use through 10-31-2002 OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**


(use as many sheets as necessary)

Street

2

**Complete if Known**

Application Number	09/479,145
Filing Date	January 7, 2000
First Named Inventor	David E. Weinstein
Group Art Unit	1647
Examiner Name	Robert C. Hayes, Ph.D.
Attorney Docket Number	96700/595



**U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature	71/10	Date Considered	6/6/03
-----------------------	-------	--------------------	--------

For the present purpose, I have omitted the first 100 pages of the original, which are largely a list of names of English-speaking Translators attached

**Written Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the results of the interview may be required to complete this form should be sent to the CIO, Information Office, U.S. Patent and Trademark Office, Washington, DC 20591.